Realizing Cyclosporin's Untapped Potential
Management of dry eye disease frequently relies on cyclosporin – but is complicated by a side-effect profile that can be too much for patients to tolerate. Could this be changed by packaging the active ingredient in a better vehicle?
sponsored by Novaliq
The high incidence of dry eye disease (DED) is well known, and its impact on quality of life is increasingly appreciated. Patients must not only endure discomfort but also accept impairments in performance of normal tasks: for example, reading speed is reduced by 14 percent in DED patients (1), and dry eye symptoms are exacerbated by reading (2). To add insult to injury, many patients cannot tolerate first-line DED therapies – cyclosporin emulsions – because of formulation derived side effects, particularly burning sensation after installation. Furthermore, these formulations are associated with large drop volumes (causing spill-over from the eye) and poor corneal spreading and retention time (reducing uptake efficiency). Hence, they do not provide optimal bioavailability and onset speed – so even when patients accept cyclosporin, they do not see its full benefit.
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.